Phoenix Biotech Acquisition Valuation
| PBAXWDelisted Stock | 0.06 0.0001 0.16% |
Phoenix Biotech seems to be overvalued based on Macroaxis valuation methodology. Our model determines the value of Phoenix Biotech Acqu from analyzing the company fundamentals such as Return On Asset of -0.0255, cash flow from operations of (1.71 M), and Total Debt of 650 K as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Phoenix Biotech's price fluctuation is very steady at this time. Calculation of the real value of Phoenix Biotech Acqu is based on 3 months time horizon. Increasing Phoenix Biotech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Phoenix stock is determined by what a typical buyer is willing to pay for full or partial control of Phoenix Biotech Acquisition. Since Phoenix Biotech is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Phoenix Stock. However, Phoenix Biotech's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.0611 | Real 0.0426 | Hype 0.06 | Naive 0.046 |
The intrinsic value of Phoenix Biotech's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Phoenix Biotech's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Phoenix Biotech Acquisition helps investors to forecast how Phoenix stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Phoenix Biotech more accurately as focusing exclusively on Phoenix Biotech's fundamentals will not take into account other important factors: Phoenix Biotech Total Value Analysis
Phoenix Biotech Acquisition is at this time anticipated to have takeover price of 0 with market capitalization of 0, debt of 650 K, and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Phoenix Biotech fundamentals before making investing decisions based on enterprise value of the companyPhoenix Biotech Asset Utilization
One of the ways to look at asset utilization of Phoenix is to check how much profit was generated for every dollar of assets it reports. Phoenix Biotech holds a negative application of assets of -0.0255 pct., losing 2.55E-4 for each of assets held by the company. Inadequate asset utilization implies the company is being less effective with each of assets it holds. Put it differently, asset utilization of Phoenix Biotech Acquisition shows how discouraging it operates for each spent on its assets.Phoenix Biotech Profitability Analysis
Net Loss for the year was (2.52 M) with profit before overhead, payroll, taxes, and interest of 0.About Phoenix Biotech Valuation
Our relative valuation model uses a comparative analysis of Phoenix Biotech. We calculate exposure to Phoenix Biotech's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Phoenix Biotech's related companies.Phoenix Biotech Acquisition Corp. intends to acquire assets and businesses through a merger, share exchange, share purchase, reorganization, or similar business combination. The company was incorporated in 2021 and is based in Oakland, California. Phoenix Biotech is traded on NASDAQ Exchange in the United States.
Phoenix Biotech Growth Indicators
Investing in growth stocks can be very risky. If the company such as Phoenix Biotech does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 17.9 M |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Other Consideration for investing in Phoenix Stock
If you are still planning to invest in Phoenix Biotech Acqu check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Phoenix Biotech's history and understand the potential risks before investing.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Stocks Directory Find actively traded stocks across global markets | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |